Clinical Trial Update: Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma who previously received PD-1/PD-L1 inhibitors has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Stivarga (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-05-30